Abstract
The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.
Original language | English (US) |
---|---|
Pages (from-to) | 1251-1265 |
Number of pages | 15 |
Journal | International journal of chronic obstructive pulmonary disease |
Volume | 14 |
DOIs | |
State | Published - Jan 1 2019 |
Keywords
- COPD
- fixed-dose combination inhalers
- LABA
- LAMA
- long-acting beta2-adrenergic agonists
- long-acting muscarinic antagonists
- umeclidinium bromide
- vilanterol trifenatate
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Health Policy
- Public Health, Environmental and Occupational Health